Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $276.92 | 12 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb, a division of Bausch Health US, LLC | $161.47 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $52.71 | 4 | $0 (2020) |
| Medtronic, Inc. | $20.74 | 1 | $0 (2023) |
| Shire North American Group Inc | $18.98 | 1 | $0 (2018) |
| Sun Pharmaceutical Industries Inc. | $12.17 | 1 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $10.85 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $20.74 | 1 | Medtronic, Inc. ($20.74) |
| 2020 | $18.02 | 1 | Novartis Pharmaceuticals Corporation ($18.02) |
| 2019 | $155.40 | 4 | Bausch & Lomb, a division of Bausch Health US, LLC ($130.62) |
| 2018 | $49.83 | 3 | Bausch & Lomb, a division of Bausch Health US, LLC ($30.85) |
| 2017 | $32.93 | 3 | Novartis Pharmaceuticals Corporation ($22.08) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/20/2023 | Medtronic, Inc. | PROPEL (Device) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 02/06/2020 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/12/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $115.96 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/08/2019 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/06/2019 | Novartis Pharmaceuticals Corporation | DUREZOL (Drug) | Food and Beverage | In-kind items and services | $12.61 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/10/2019 | Sun Pharmaceutical Industries Inc. | XELPROS (Drug) | Food and Beverage | Cash or cash equivalent | $12.17 | General |
| Category: Ophthalmology | ||||||
| 08/13/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/09/2018 | Shire North American Group Inc | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: OPTHALMICS | ||||||
| 01/23/2018 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/13/2017 | Novartis Pharmaceuticals Corporation | ILEVRO (Drug) | Food and Beverage | In-kind items and services | $11.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/16/2017 | Valeant Pharmaceuticals North America LLC | LOTEMAX GEL (Drug), PROLENSA | Food and Beverage | In-kind items and services | $10.85 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/06/2017 | Novartis Pharmaceuticals Corporation | ILEVRO (Drug) | Food and Beverage | In-kind items and services | $10.86 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 100 | 106 | $28,952 | $9,357 |
| 2020 | 7 | 187 | 201 | $20,135 | $8,763 |
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 39 | $13,338 | $3,860 | 28.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 41 | $9,348 | $2,829 | 30.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 26 | 26 | $6,266 | $2,669 | 42.6% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 54 | 56 | $7,280 | $3,523 | 48.4% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 51 | 59 | $5,310 | $1,775 | 33.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 25 | $2,750 | $1,516 | 55.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 17 | $1,275 | $872.90 | 68.5% |
| 92083 | Measurement of field of vision during daylight conditions | Office | 2020 | 14 | 14 | $1,120 | $434.35 | 38.8% |
| 92250 | Photography of the retina | Office | 2020 | 17 | 17 | $1,360 | $380.34 | 28.0% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2020 | 13 | 13 | $1,040 | $260.55 | 25.1% |
About Dr. Patrick Lally, MD
Dr. Patrick Lally, MD is a Ophthalmology healthcare provider based in Latrobe, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1447253331.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Lally, MD has received a total of $276.92 in payments from pharmaceutical and medical device companies, with $20.74 received in 2023. These payments were reported across 12 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($276.92).
As a Medicare-enrolled provider, Lally has provided services to 287 Medicare beneficiaries, totaling 307 services with total Medicare billing of $18,121. Data is available for 2 years (2020–2023), covering 10 distinct procedure/service records.
Practice Information
- Specialty Ophthalmology
- Location Latrobe, PA
- Active Since 05/24/2005
- Last Updated 07/08/2007
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1447253331
Products in Payments
- VYZULTA (Drug) $161.47
- XIIDRA (Drug) $37.00
- ILEVRO (Drug) $22.08
- PROPEL (Device) $20.74
- DUREZOL (Drug) $12.61
- XELPROS (Drug) $12.17
- LOTEMAX GEL (Drug) $10.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.